{"id":"advair-250","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nervousness"},{"rate":null,"effect":"Oral candidiasis"},{"rate":null,"effect":"Palpitations"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluticasone propionate suppresses inflammatory responses in the airways by binding glucocorticoid receptors, reducing mucus production and airway edema. Salmeterol activates beta-2 adrenergic receptors on bronchial smooth muscle, causing sustained bronchodilation. Together, they provide both anti-inflammatory and bronchodilatory effects for maintenance asthma and COPD control.","oneSentence":"Advair 250 combines an inhaled corticosteroid (fluticasone) and a long-acting beta-2 agonist (salmeterol) to reduce airway inflammation and improve bronchial smooth muscle relaxation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:20:07.190Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance treatment"},{"name":"Chronic obstructive pulmonary disease (COPD) maintenance treatment"}]},"trialDetails":[{"nctId":"NCT01202097","phase":"PHASE3","title":"A Non- Inferiority Comparative Study Between Seretide® and Salmeterol/Fluticasone Eurofarma in Patients with Asthma","status":"COMPLETED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2011-08","conditions":"Asthma","enrollment":334},{"nctId":"NCT00424008","phase":"PHASE3","title":"Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-04","conditions":"Asthma","enrollment":722},{"nctId":"NCT00379288","phase":"PHASE3","title":"Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-06","conditions":"Asthma","enrollment":404},{"nctId":"NCT00235053","phase":"PHASE4","title":"Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID","status":"COMPLETED","sponsor":"Allergy & Asthma Medical Group & Research Center","startDate":"2005-08","conditions":"Asthma, Candidiasis, Oral, Voice Disorders","enrollment":13},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT01225913","phase":"PHASE4","title":"Mechanism(s) of Airflow Limitation During Exacerbation of Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10","conditions":"Asthma","enrollment":50},{"nctId":"NCT05982990","phase":"PHASE1","title":"Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers","status":"UNKNOWN","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2023-08-01","conditions":"Bioequivalence","enrollment":34},{"nctId":"NCT04503460","phase":"PHASE4","title":"Mechanisms of Adverse Effects of Long-Acting Beta-Agonists in Asthma","status":"UNKNOWN","sponsor":"Imperial College London","startDate":"2021-07-23","conditions":"Asthma","enrollment":24},{"nctId":"NCT02215122","phase":"PHASE1","title":"Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs","status":"COMPLETED","sponsor":"Mylan Pharma UK Ltd.","startDate":"2013-10","conditions":"Asthma, COPD","enrollment":40},{"nctId":"NCT00250341","phase":"PHASE4","title":"Non-invasive Measures of Distal Lung Disease in Asthmatics","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2005-09-30","conditions":"Asthma","enrollment":34},{"nctId":"NCT02437604","phase":"PHASE1","title":"Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2015-05","conditions":"Asthma","enrollment":43},{"nctId":"NCT02175771","phase":"PHASE3","title":"Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-07","conditions":"Persistent Asthma","enrollment":758},{"nctId":"NCT05085587","phase":"PHASE1","title":"Bioequivalence Study of Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers","status":"UNKNOWN","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2021-10-01","conditions":"Bioequivalence, Asthma","enrollment":18},{"nctId":"NCT04746040","phase":"PHASE1","title":"A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers","status":"UNKNOWN","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2021-01-18","conditions":"Bioequivalence, Asthma","enrollment":50},{"nctId":"NCT02924688","phase":"PHASE3","title":"A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-10-13","conditions":"Asthma","enrollment":2436},{"nctId":"NCT04790838","phase":"","title":"Pooled Analysis FP_SX_250_50","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2019-06-02","conditions":"Asthma","enrollment":82},{"nctId":"NCT04466176","phase":"PHASE1","title":"A Pivotal Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2020-07-01","conditions":"Bioequivalence","enrollment":34},{"nctId":"NCT04462822","phase":"PHASE1","title":"A Pilot Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2020-08-24","conditions":"Bioequivalence","enrollment":14},{"nctId":"NCT02833480","phase":"PHASE2","title":"A Study to Investigate the Differential Effects of Inhaled Symbicort and Advair on Lung Microbiota","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2015-02","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":69},{"nctId":"NCT03207243","phase":"PHASE2","title":"Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-09-14","conditions":"Asthma","enrollment":165},{"nctId":"NCT02251379","phase":"PHASE2","title":"Environmental Control as Add-on Therapy in Childhood Asthma","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2014-10-01","conditions":"Asthma","enrollment":155},{"nctId":"NCT01794780","phase":"PHASE4","title":"A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-02-05","conditions":"COPD","enrollment":2229},{"nctId":"NCT03894280","phase":"PHASE1","title":"A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade (BREATH-PK250-CC)","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2019-03-12","conditions":"Bioequivalence","enrollment":36},{"nctId":"NCT03387241","phase":"PHASE3","title":"Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 Years","status":"UNKNOWN","sponsor":"Mundipharma (China) Pharmaceutical Co. Ltd","startDate":"2017-06-02","conditions":"Asthma","enrollment":330},{"nctId":"NCT01194700","phase":"PHASE4","title":"Comparative Study of Lung Bioavailability of HFA-Seretide Via Current Spacer Devices in Healthy Volunteers","status":"COMPLETED","sponsor":"Brian J Lipworth","startDate":"2009-11","conditions":"Asthma","enrollment":19},{"nctId":"NCT00731770","phase":"PHASE4","title":"Comparing Fluticasone-salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2009-01","conditions":"COPD","enrollment":10},{"nctId":"NCT03820180","phase":"PHASE1","title":"A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2019-01-23","conditions":"Bioequivalence","enrollment":34},{"nctId":"NCT01696214","phase":"PHASE4","title":"A Pilot Study to Determine the Feasibility and Utility of Implementing of the Full Scale TOM Trial","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2012-10","conditions":"Asthma","enrollment":20},{"nctId":"NCT02061280","phase":"PHASE4","title":"Use of Mobile Devices and the Internet to Streamline an Asthma Clinical Trial","status":"COMPLETED","sponsor":"Nemours Children's Clinic","startDate":"2013-10","conditions":"Asthma","enrollment":108},{"nctId":"NCT03745261","phase":"PHASE3","title":"Effect of Yong Chong Cao Capsule on Outcomes in Patients With Mild to Severe COPD","status":"UNKNOWN","sponsor":"Henan University of Traditional Chinese Medicine","startDate":"2018-06-20","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":240},{"nctId":"NCT01967173","phase":"PHASE3","title":"Best African American Response to Asthma Drugs","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2014-02","conditions":"Asthma","enrollment":574},{"nctId":"NCT01462344","phase":"PHASE4","title":"6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11-17","conditions":"Asthma","enrollment":6250},{"nctId":"NCT01475721","phase":"PHASE4","title":"SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11-18","conditions":"Asthma","enrollment":11751},{"nctId":"NCT00395304","phase":"PHASE3","title":"Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER)","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2007-03","conditions":"Asthma","enrollment":182},{"nctId":"NCT02491970","phase":"PHASE4","title":"Small Airway Function of Fluticasone/Formoterol (Flutiform®) and Fluticasone/Salmeterol","status":"TERMINATED","sponsor":"Mundipharma Korea Ltd","startDate":"2015-08-31","conditions":"Asthma","enrollment":15},{"nctId":"NCT03238482","phase":"PHASE1","title":"Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus (SAIMI)","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2017-08-16","conditions":"Asthma","enrollment":64},{"nctId":"NCT00363480","phase":"PHASE4","title":"Results Of Patient Rated Asthma Control Test In Comparison To Diary Card Data","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05-17","conditions":"Asthma","enrollment":221},{"nctId":"NCT00455923","phase":"PHASE4","title":"SERETIDE Vs FLIXOTIDE In Mild Persistent Asthma (GINAII)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-05-03","conditions":"Asthma","enrollment":100},{"nctId":"NCT01110200","phase":"PHASE4","title":"Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-04-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":639},{"nctId":"NCT01124422","phase":"PHASE4","title":"Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-19","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":255},{"nctId":"NCT01817764","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":707},{"nctId":"NCT00351143","phase":"PHASE4","title":"A Comparative Study To Determine If Motivating Asthma Education (Compliance Enhancement) Has An Effect On Asthma Control","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-07-26","conditions":"Asthma","enrollment":274},{"nctId":"NCT01331694","phase":"","title":"Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":76130},{"nctId":"NCT01337336","phase":"","title":"Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a COPD-Comorbid Depression/Anxiety Population","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1},{"nctId":"NCT01347060","phase":"","title":"Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol Xinafoate Combination Versus Inhaled Corticosteroids or Other Combination Therapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07","conditions":"Asthma","enrollment":17448},{"nctId":"NCT01381458","phase":"","title":"Risk of Re-Hospitalization in Patients With Chronic Obstructive Pulmonary Disease (COPD) Post Exacerbation","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1936},{"nctId":"NCT01387178","phase":"","title":"Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salmeterol 50 (FSC) or Tiotropium in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":22223},{"nctId":"NCT01395875","phase":"","title":"Outcomes for Chronic Obstructive Pulmonary Disease Moderate Exacerbators Initiating Treatment","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2849},{"nctId":"NCT01437995","phase":"PHASE4","title":"Long-acting Beta Agonist Step Down Study","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2012-03","conditions":"Asthma","enrollment":459},{"nctId":"NCT02165826","phase":"PHASE3","title":"Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-05-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1323},{"nctId":"NCT02055352","phase":"PHASE4","title":"Study to Evaluate Efficacy/Safety of Combination Budesonide/Indacaterol vs Fluticasone/Salmeterol in Patients With COPD","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-05-30","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":222},{"nctId":"NCT00901368","phase":"PHASE4","title":"FACTO Study (Foster® As Complete Treatment Option)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2009-05","conditions":"Asthmatic Patients","enrollment":431},{"nctId":"NCT02195375","phase":"PHASE2, PHASE3","title":"Flutiform® Compared With Seretide® in the Treatment of COPD","status":"COMPLETED","sponsor":"Mundipharma Research Limited","startDate":"2014-09","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":923},{"nctId":"NCT01393145","phase":"PHASE3","title":"Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPD","status":"WITHDRAWN","sponsor":"Ache Laboratorios Farmaceuticos S.A.","startDate":"2011-08","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":""},{"nctId":"NCT00857766","phase":"PHASE4","title":"A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":249},{"nctId":"NCT00115492","phase":"PHASE4","title":"Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":797},{"nctId":"NCT02441114","phase":"PHASE1","title":"Pharmacokinetics of Co-administration of Seretide 250 Diskus (HCP0910) and Spiriva Capsule for Inhalation (HGP1011)","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2015-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":10},{"nctId":"NCT00974246","phase":"PHASE4","title":"The Effect on Depressive Symptoms in ECF Residents With COPD","status":"COMPLETED","sponsor":"Valley Medical Research","startDate":"2009-10","conditions":"Chronic Obstructive Pulmonary Disease, Depression","enrollment":30},{"nctId":"NCT00452348","phase":"PHASE4","title":"A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05","conditions":"Asthma","enrollment":628},{"nctId":"NCT00452699","phase":"PHASE4","title":"A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05","conditions":"Asthma","enrollment":621},{"nctId":"NCT00633217","phase":"PHASE4","title":"Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":247},{"nctId":"NCT00784550","phase":"PHASE4","title":"A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":342},{"nctId":"NCT00144911","phase":"PHASE4","title":"ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":740},{"nctId":"NCT00346749","phase":"PHASE4","title":"ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Group of Companies.","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2006-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":180},{"nctId":"NCT00479739","phase":"PHASE4","title":"CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-11","conditions":"Asthma","enrollment":700},{"nctId":"NCT01231230","phase":"NA","title":"Interactive Acute Smooth Muscle Effects of Salmeterol and Fluticasone in the Airway","status":"COMPLETED","sponsor":"University of Miami","startDate":"2007-05","conditions":"Asthma","enrollment":14},{"nctId":"NCT02782312","phase":"PHASE4","title":"Salmeterol-Fluticasone Combined Inhaled Therapy for Non-cystic Fibrosis Bronchiectasis","status":"COMPLETED","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2011-06","conditions":"Bronchiectasis","enrollment":120},{"nctId":"NCT00741767","phase":"NA","title":"The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2008-08","conditions":"Chronic Obstructive Pulmonary Disease, Sleep Disorders","enrollment":""},{"nctId":"NCT02546349","phase":"PHASE4","title":"Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS/LABA Versus LAMA","status":"UNKNOWN","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2014-07","conditions":"COPD","enrollment":143},{"nctId":"NCT00568347","phase":"","title":"Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange","status":"COMPLETED","sponsor":"Arthur F Gelb MD","startDate":"2006-01","conditions":"COPD","enrollment":39},{"nctId":"NCT02318043","phase":"NA","title":"AMP-BPT and His-BPT for Assessment of Asthma","status":"COMPLETED","sponsor":"Guangzhou Institute of Respiratory Disease","startDate":"2007-01","conditions":"Asthma","enrollment":84},{"nctId":"NCT01209715","phase":"PHASE2","title":"Effect of an Inhaled Glucocorticoid-long-acting Beta Adrenergic Agonist on Endothelial Function in COPD","status":"WITHDRAWN","sponsor":"University of Miami","startDate":"2010-10","conditions":"COPD","enrollment":""},{"nctId":"NCT02136875","phase":"PHASE4","title":"Strategy for Early Treatment of Exacerbations in COPD: Standing Prescriptions of Advair With a Written Action Plan in the Event of an Exacerbation","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2008-07","conditions":"COPD, Chronic Obstructive Pulmonary Disease","enrollment":37},{"nctId":"NCT01795664","phase":"PHASE3","title":"Compare the Effects of Seretide® Evohaler and a Generic Salmeterol/Fluticasone Hydrofluoroalkane (HFA) Pressurized Metered-dose Inhaler (pMDI) on Functional Respiratory Imaging Parameters in Asthmatic Patients","status":"COMPLETED","sponsor":"FLUIDDA nv","startDate":"2013-03","conditions":"Asthma","enrollment":16},{"nctId":"NCT01521455","phase":"PHASE1","title":"Therapeutic Equivalence Study of HCP0910 250/50 Mcg to Seretide 250 Diskus in Asthmatic Patients","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2012-02","conditions":"Asthma","enrollment":56},{"nctId":"NCT00557440","phase":"PHASE2","title":"Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-11","conditions":"Asthma","enrollment":37},{"nctId":"NCT01431924","phase":"","title":"Observed Outcomes Associated With Fluticasone Propionate/Salmeterol Xinafoate or Inhaled Corticosteroids in Asthma Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10","conditions":"Asthma","enrollment":7779},{"nctId":"NCT00559312","phase":"NA","title":"The Effect of Fluticasone/Salmeterol Combination on Exertional Breathlessness in Patients With Mild COPD","status":"COMPLETED","sponsor":"Queen's University","startDate":"2007-12","conditions":"COPD","enrollment":18},{"nctId":"NCT00480649","phase":"PHASE4","title":"Successful Control and Clinical Effectiveness Of SERETIDE(Salmeterol/Fluticasone Propionate) Study In Asthma.(SUCCESS)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-01","conditions":"Asthma","enrollment":424},{"nctId":"NCT01647646","phase":"PHASE4","title":"Real Life Effectiveness in Patients With Not Optimally Controlled Asthma","status":"COMPLETED","sponsor":"Far Eastern Memorial Hospital","startDate":"2009-03","conditions":"Asthma","enrollment":200},{"nctId":"NCT00262587","phase":"PHASE4","title":"Elite Sport and Development of Asthma","status":"COMPLETED","sponsor":"Bispebjerg Hospital","startDate":"2005-09","conditions":"Asthma","enrollment":18},{"nctId":"NCT00784485","phase":"PHASE4","title":"Non-invasive Measures of Effects of Xolair in Asthma","status":"TERMINATED","sponsor":"University of California, Los Angeles","startDate":"2009-02","conditions":"Asthma","enrollment":13},{"nctId":"NCT01255579","phase":"PHASE4","title":"Effects on Small Airways of Two Long-term Extrafine Treatments in Asthma","status":"COMPLETED","sponsor":"Università degli Studi di Brescia","startDate":"2007-07","conditions":"Bronchial Asthma","enrollment":10},{"nctId":"NCT01186653","phase":"PHASE4","title":"Effect on Adrenal Function of Budesonide Versus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Hull University Teaching Hospitals NHS Trust","startDate":"2007-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":22},{"nctId":"NCT01131806","phase":"PHASE4","title":"Comparing Treatment Efficacy With HD/MD Flu Plus Sal in Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"UNKNOWN","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2009-12","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":124},{"nctId":"NCT00908362","phase":"PHASE1","title":"Impact of Fluticasone and Salmeterol on Airway Dendritic Cells (DCs) in Smokers","status":"COMPLETED","sponsor":"University of Rostock","startDate":"2009-05","conditions":"Smoke-related Lung Diseases, Chronic Obstructive Pulmonary Disease","enrollment":45},{"nctId":"NCT00403286","phase":"PHASE2","title":"A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Dey","startDate":"2006-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":457},{"nctId":"NCT00252863","phase":"PHASE3","title":"DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-12","conditions":"Asthma","enrollment":1600},{"nctId":"NCT00575861","phase":"PHASE4","title":"Zileuton and Exhaled Nitric Oxide in Asthmatics","status":"COMPLETED","sponsor":"Gelb, Arthur F., M.D.","startDate":"2005-09","conditions":"Asthma","enrollment":19}],"_emaApprovals":[],"_faersSignals":[{"count":7,"reaction":"FATIGUE"},{"count":7,"reaction":"NAUSEA"},{"count":6,"reaction":"DYSPNOEA"},{"count":6,"reaction":"INFLUENZA"},{"count":6,"reaction":"PNEUMONIA"},{"count":5,"reaction":"INSOMNIA"},{"count":5,"reaction":"VOMITING"},{"count":4,"reaction":"DIARRHOEA"},{"count":4,"reaction":"HYPERHIDROSIS"},{"count":4,"reaction":"MUSCLE SPASMS"}],"_approvalHistory":[],"publicationCount":479,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["fluticasone/salmeterol 250/50"],"phase":"marketed","status":"active","brandName":"Advair 250","genericName":"Advair 250","companyName":"Milton S. Hershey Medical Center","companyId":"milton-s-hershey-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Advair 250 combines an inhaled corticosteroid (fluticasone) and a long-acting beta-2 agonist (salmeterol) to reduce airway inflammation and improve bronchial smooth muscle relaxation. Used for Asthma maintenance treatment, Chronic obstructive pulmonary disease (COPD) maintenance treatment.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}